Transfection News and Research

RSS

Study findings have potential to advance treatments for small cell lung cell cancer

Two recently published studies by a research team at University Hospitals Case Medical Center Seidman Cancer Center have the potential to advance treatments for small cell lung cell cancer (SCLC). This aggressive form of lung cancer has seen no treatment advances in 30 years and "is a disease in urgent need of new drug therapies," write the study's authors.

26 Sep 2014

GW researcher awarded grant to develop a model system to study PN infection

According to a recent World Health Organization report of the leading causes of death worldwide, one-third of all deaths are due to infectious and parasitic diseases. There are currently no vaccines for parasitic nematode (PN), or worm infections in humans, and development of new drugs and vaccines will stall until researchers have a better understanding of PN biology.

11 Aug 2014

Celsion announces financial results for second quarter ended 2014

Celsion Corporation, an oncology drug development company, today announced financial results for the second quarter ended June 30, 2014.

7 Aug 2014

Celsion signs definitive asset purchase agreement to acquire EGEN

Celsion Corporation (Celsion) (NASDAQ: CLSN), an oncology drug development company, and EGEN, Inc. (EGEN), a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases, today announced the signing of a definitive asset purchase agreement in which Celsion will acquire substantially all of the assets of EGEN, including its Phase Ib DNA-based immunotherapy product candidate EGEN-001 and its therapeutic platform technologies, TheraPlas™ for delivery of DNA and mRNA, TheraSilence™ for delivery of RNA, and RAST™ for Cell Enabled Expression and Secretion of RNA.

10 Jun 2014

Polyplus-transfection introduces FectoPRO transfection reagent

Polyplus-transfection SA, a privately-held company specializing in the development of innovative solutions for transfection, today announces the launch of FectoPRO, the latest optimised transfection reagent in their product portfolio. FectoPRO has been designed for high yields in medium and large-scale production of proteins and antibodies in mammalian cells.

28 May 2014

European Commission approves Exelixis' COMETRIQ for treatment of progressive, metastatic MTC

Exelixis, Inc. today announced that the European Commission has approved COMETRIQ (cabozantinib) for the treatment of adult patients with progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma (MTC).

25 Mar 2014

Polyplus-transfection grants research license to NIH for PEI-mediated transfection applications

Polyplus-transfection SA, a privately-held company developing innovative technologies for molecular and cellular biology, announces today that it has granted two agencies of the United States National Institutes of Health a non-exclusive, research license to use Polyethylenimine (PEI) for in vitro transfection applications. The two agencies are the National Institute of Allergy and Infectious Diseases and the National Cancer Institute.

17 Feb 2014

RNAi-based screening offers MPM treatment hope

Research using RNA interference-based screening has identified several potential targets for the treatment of malignant pleural mesothelioma.

31 Jan 2014

Researchers discover way to use stem cells as drug delivery vehicles

A group of Brigham and Women's Hospital, and Harvard Stem Cell Institute researchers and collaborators at MIT and MGH have found a way to use stem cells as drug delivery vehicles.

5 Oct 2013

Cellectricon awards Cellaxess ACE project grant to support research in cell biology

Cellectricon, a leading provider of advanced cell-based screening technologies and services, has announced the two winners of its Cellaxess ACE project grant, supporting cutting-edge research in cell biology.

From Cellectricon 21 Sep 2013

Ret enzyme may be a novel therapeutic target in selected groups of breast cancer patients

Scientists at the MedUni Vienna, in collaboration with a working group led by Nancy Hynes at the University of Basel, have discovered a new approach in the treatment of breast cancer: an international team involving the Clinical Institute of Pathology at the MedUni Vienna has been able to demonstrate the activation of a receptor, the Ret protein (Rearranged during transfection), on the surface of breast cancer cells. Increased levels of this protein are associated with a lower likelihood of survival for breast cancer patients.

8 Aug 2013

High-tech laser technique offers control of gene therapy and genetic engineering method

The applications of gene therapy and genetic engineering are broad: everything from pet fish that glow red to increased crop yields worldwide to cures for many of the diseases that plague humankind.

8 Aug 2013

Protein on surface of human breast tumour cells may serve as drug target for breast cancer

Scientists have identified higher levels of a receptor protein found on the surface of human breast tumour cells that may serve as a new drug target for the treatment of breast cancer.

19 Jul 2013

Researchers develop new method for delivering molecules into targeted single cells through temporary holes

Northwestern University researchers have developed a new method for delivering molecules into single, targeted cells through temporary holes in the cell surface. The technique could find applications in drug delivery, cell therapy, and related biological fields.

22 May 2013

Mirus Bio to use CSIRO's RAFT Polymerization Technology to expedite its product development efforts

CSIRO and Mirus Bio LLC are pleased to announce a new license arrangement that will enable Mirus Bio to utilize the unique characteristics of CSIRO's Reversible Addition-Fragmentation chain Transfer polymerisation technology (RAFT) to expand upon its high-end polymer development capabilities for the biotech industry.

22 Apr 2013

Novel nanoparticle-based approach enables more efficient delivery of siRNA drugs

New classes of drugs that can silence specific genes, such as small interfering RNAs (siRNAs), offer great therapeutic potential. But the specific delivery of siRNAs to target cells to exert their effects remains a significant challenge. A novel nanoparticle-based approach that enables more efficient delivery of siRNA drugs is presented in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc. publishers.

12 Apr 2013

Biomedical professor details research progress toward reading, writing neural code

Despite many remarkable discoveries in the field of neuroscience during the past several decades, researchers have not been able to fully crack the brain's "neural code."

13 Mar 2013

UPC develops new system for electroporation of cell cultures

Researchers from the Polytechnic University of Catalonia have developed a technique that improves and cuts the cost of a technique called electroporation, which involves opening pores in cell membranes using an electric field to introduce substances like drugs and DNA. Current methods are aggressive and expensive whereas the new system manages to apply low voltage electroporation with a small printed circuit board, which costs less than a Euro per unit and does not damage cells.

11 Feb 2013

UPC teams conduct research in biomedical engineering to improve people's health

Systems to improve patient rehabilitation, methods that help detect diseases, and smart biomaterials for optimising treatments—scientific advances in the field of biomedical engineering are unstoppable. A number of leading UPC teams are carrying out research aimed at harnessing technology to improve people's health.

23 Nov 2012

RRM2 may be a facilitating factor in colorectal cancer and UV-induced DNA damage repair

Colorectal cancer (CRC) is the leading cause of cancer-related death worldwide. In addition, the incidence and mortality rates of colorectal cancer are on the rise. Recently, metabolic genes have received increasing and specific attention due to their potential role in carcinogenesis.

20 Sep 2012